These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 26004874)

  • 1. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
    Dupont H; Marciniak S; Zogheib E; Mammeri H; Friggeri A; Ammenouche N; Levrard M; Airapetian N; Tinturier F; Mahjoub Y
    Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.
    Dubois V; Arpin C; Melon M; Melon B; Andre C; Frigo C; Quentin C
    J Clin Microbiol; 2001 Jun; 39(6):2072-8. PubMed ID: 11376037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
    Moya B; Zamorano L; Juan C; Pérez JL; Ge Y; Oliver A
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M
    Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
    Berrazeg M; Jeannot K; Ntsogo Enguéné VY; Broutin I; Loeffert S; Fournier D; Plésiat P
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6248-55. PubMed ID: 26248364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between cefepime utilisation and Pseudomonas aeruginosa resistance rates to β-lactams and carbapenems in patients with healthcare-associated infections.
    Djordjevic ZM; Folic MM; Jankovic SM
    J Glob Antimicrob Resist; 2018 Jun; 13():60-64. PubMed ID: 29154953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa.
    Naesens R; Vlieghe E; Verbrugghe W; Jorens P; Ieven M
    BMC Infect Dis; 2011 Nov; 11():317. PubMed ID: 22085766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
    Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
    Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes.
    Lucena A; Dalla Costa LM; Nogueira KS; Matos AP; Gales AC; Paganini MC; Castro ME; Raboni SM
    J Hosp Infect; 2014 Aug; 87(4):234-40. PubMed ID: 25027563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
    Chen YH; Peng CF; Lu PL; Tsai JJ; Chen TP
    Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.
    Micek ST; Wunderink RG; Kollef MH; Chen C; Rello J; Chastre J; Antonelli M; Welte T; Clair B; Ostermann H; Calbo E; Torres A; Menichetti F; Schramm GE; Menon V
    Crit Care; 2015 May; 19(1):219. PubMed ID: 25944081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
    Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
    Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.
    Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B
    Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria.
    Strateva T; Ouzounova-Raykova V; Markova B; Todorova A; Marteva-Proevska Y; Mitov I
    J Chemother; 2007 Apr; 19(2):140-5. PubMed ID: 17434821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
    Cho HH; Kwon GC; Kim S; Koo SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.